Volume XXVIII, No. 16 – November 29, 2021
In this issue:
Two distinctly different bills have surfaced in Congress, each with the potential to have substantial impact on how laboratory-developed tests (LDTs) are regulated by agencies of the federal government. Also, an attorney with decades of experience in advising clinical labs on CLIA matters analyzes the lessons to be learned for lab directors in the Elizabeth Holmes trial.